Willmann S., Marostica E., Snelder N., Solms A., Jensen M., Lobmeyer M., Lensing A. W. A., Bethune C., Morgan E., Yu R. Z., Wang Y., Jung S. W., Geary R., Bhanot S. PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients. CPT Pharmacometrics Syst. Pharmacol. 10(8): 890–901, 2021. [Link to publication]